Dynamic trajectories of sepsis-induced immunoparalysis: from biological mechanisms to precision monitoring and targeted intervention
5 affiliations
- 1Department of Critical Care Medicine, The Affiliated Hospital, Southwest Medical University
- 2School of Clinical Medicine, Southwest Medical University
- 3School of Medical Imaging, Southwest Medical University
- 4School of Public Health, Southwest Medical University
- 5Department of Gastroenterology, Xuyong County People’s Hospital
Abstract
Sepsis is increasingly recognized as a heterogeneous syndrome in which profound immunosuppression, or immunoparalysis, may coexist with or follow the initial hyperinflammatory response. This state is characterized by impaired host responsiveness to pathogens and secondary immune stimuli and is associated with secondary infections, persistent organ dysfunction, and increased mortality. This narrative review summarizes the conceptual evolution and biological basis of sepsis-induced immunoparalysis, with particular emphasis on innate immune deactivation, adaptive immune dysfunction, immune-checkpoint upregulation, and metabolic-epigenetic reprogramming. A central focus is the transition from static, single-time-point assessment toward longitudinal characterization of immune trajectories. Current evidence suggests that the first 1–2 weeks after sepsis onset represent a critical period during which heterogeneous recovery patterns become apparent. Empirically supported patterns include improving or recovering immune states and persistent hyporesponsiveness, whereas fluctuating transitions remain a proposed, hypothesis-generating trajectory requiring further longitudinal validation. We review major monitoring indicators, including monocyte human leukocyte antigen-DR (mHLA-DR), absolute lymphocyte count (ALC), ex vivo cytokine production capacity, and immune checkpoints such as programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1). Importantly, most currently available biomarkers have stronger evidence for immune phenotyping and prognostic assessment than for predicting treatment response, and reported thresholds remain dependent on assay methodology, patient population, and measurement timing. We further discuss emerging biomarker-guided approaches, including the ImmunoSep trial, as early proof-of-concept for phenotype-enriched immunotherapy rather than definitive evidence for routine clinical implementation. Overall, repeated multi-marker assessment may improve characterization of immune trajectories and help identify candidate treatment-eligible windows; however, biomarker-based treatment thresholds, composite immune-clinical frameworks, and phenotype-matched immunotherapies require further prospective validation, particularly with respect to mortality, safety, and other patient-important outcomes.
Related
- From maturation to degeneration: Distinct biological trajectories in bicuspid and tricuspid aortopathy
- Weight Loss and Long-Term Weight Trajectories After a Structured Nutritional and Behavioral Intervention: A Large Real-World Cohort Study
- Longitudinal Trajectories of Autonomic Maturation in Preterm Infants Using Serial 24-Hour Heart Rate Variability Monitoring.
- Ultra-Processed Foods in Early Life: Biological Mechanisms, Developmental Programming and Childhood Obesity—A Narrative Review
- The Dark Side of Radiotherapy: Experimental Evidence, Biological Mechanisms, and Preventive Strategies for Radiation-Induced Tumor-Promoting Niches
BibTeX
@article{xue2026dynamic,
title = {{Dynamic trajectories of sepsis-induced immunoparalysis: from biological mechanisms to precision monitoring and targeted intervention}},
author = {Chengxin Xue and Yiheng Hu and Xinyun Wu and Yudan Chen and Zihao Zhou and Qidong Jiang and Bo Yang and Chengli Wen},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1933094},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1933094/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Dynamic trajectories of sepsis-induced immunoparalysis: from biological mechanisms to precision monitoring and targeted intervention
AU - Chengxin Xue
AU - Yiheng Hu
AU - Xinyun Wu
AU - Yudan Chen
AU - Zihao Zhou
AU - Qidong Jiang
AU - Bo Yang
AU - Chengli Wen
PY - 2026
DA - 2026/10/16
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1933094
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1933094/full
AB - Sepsis is increasingly recognized as a heterogeneous syndrome in which profound immunosuppression, or immunoparalysis, may coexist with or follow the initial hyperinflammatory response. This state is characterized by impaired host responsiveness to pathogens and secondary immune stimuli and is associated with secondary infections, persistent organ dysfunction, and increased mortality. This narrative review summarizes the conceptual evolution and biological basis of sepsis-induced immunoparalysis, with particular emphasis on innate immune deactivation, adaptive immune dysfunction, immune-checkpoint upregulation, and metabolic-epigenetic reprogramming. A central focus is the transition from static, single-time-point assessment toward longitudinal characterization of immune trajectories. Current evidence suggests that the first 1–2 weeks after sepsis onset represent a critical period during which heterogeneous recovery patterns become apparent. Empirically supported patterns include improving or recovering immune states and persistent hyporesponsiveness, whereas fluctuating transitions remain a proposed, hypothesis-generating trajectory requiring further longitudinal validation. We review major monitoring indicators, including monocyte human leukocyte antigen-DR (mHLA-DR), absolute lymphocyte count (ALC), ex vivo cytokine production capacity, and immune checkpoints such as programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1). Importantly, most currently available biomarkers have stronger evidence for immune phenotyping and prognostic assessment than for predicting treatment response, and reported thresholds remain dependent on assay methodology, patient population, and measurement timing. We further discuss emerging biomarker-guided approaches, including the ImmunoSep trial, as early proof-of-concept for phenotype-enriched immunotherapy rather than definitive evidence for routine clinical implementation. Overall, repeated multi-marker assessment may improve characterization of immune trajectories and help identify candidate treatment-eligible windows; however, biomarker-based treatment thresholds, composite immune-clinical frameworks, and phenotype-matched immunotherapies require further prospective validation, particularly with respect to mortality, safety, and other patient-important outcomes.
SN - 1664-3224
ER -